The Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; the Botswana Harvard AIDS Institute Partnership, the Department of Internal Medicine, University of Botswana, the Ministry of Health and Wellness, and the Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana; and the Department of Obstetrics and Gynecology and the Division of Infectious Diseases, Beth Israel Deaconess Medical Center, the Division of Infectious Diseases, Brigham and Women's Hospital, and the Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Obstet Gynecol. 2023 Jan 1;141(1):135-143. doi: 10.1097/AOG.0000000000005020. Epub 2022 Nov 30.
To evaluate the combined association of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human immunodeficiency virus (HIV) infection on adverse birth outcomes in an HIV-endemic region.
The Tsepamo Study abstracts data from antenatal and obstetric records in government maternity wards across Botswana. We assessed maternal mortality and adverse birth outcomes for all singleton pregnancies from September 2020 to mid-November 2021 at 13 Tsepamo sites among individuals with documented SARS-CoV-2 screening tests and known HIV status.
Of 20,410 individuals who gave birth, 11,483 (56.3%) were screened for SARS-CoV-2 infection; 4.7% tested positive. People living with HIV were more likely to test positive (144/2,421, 5.9%) than those without HIV (392/9,030, 4.3%) (P=.001). Maternal deaths occurred in 3.7% of those who had a positive SARS-CoV-2 test result compared with 0.1% of those who tested negative (adjusted relative risk [aRR] 31.6, 95% CI 15.4-64.7). Maternal mortality did not differ by HIV status. The offspring of individuals with SARS-CoV-2 infection experienced more overall adverse birth outcomes (34.5% vs 26.6%; aRR 1.2, 95% CI 1.1-1.4), severe adverse birth outcomes (13.6% vs 9.8%; aRR 1.2, 95% CI 1.0-1.5), preterm delivery (21.4% vs 13.4%; aRR 1.4, 95% CI 1.2-1.7), and stillbirth (5.6% vs 2.7%; aRR 1.7 95% CI 1.2-2.5). Neonates exposed to SARS-CoV-2 and HIV infection had the highest prevalence of adverse birth outcomes (43.1% vs 22.6%; aRR 1.7, 95% CI 1.4-2.0).
Infection with SARS-CoV-2 at the time of delivery was associated with 3.7% maternal mortality and 5.6% stillbirth in Botswana. Most adverse birth outcomes were worse among neonates exposed to both SARS-CoV-2 and HIV infection.
在艾滋病流行地区,评估严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)和人类免疫缺陷病毒(HIV)感染合并对不良出生结局的影响。
Tsepamo 研究从博茨瓦纳政府产科病房的产前和产科记录中提取数据。我们评估了 2020 年 9 月至 2021 年 11 月中旬在 13 个 Tsepamo 地点接受过 SARS-CoV-2 筛查检测且已知 HIV 状况的所有单胎妊娠的孕产妇死亡率和不良出生结局。
在 20410 名分娩的个体中,有 11483 名(56.3%)接受了 SARS-CoV-2 感染筛查;有 4.7%的人检测结果呈阳性。与未感染 HIV 的人(392/9030,4.3%)相比,感染 HIV 的人更有可能检测呈阳性(144/2421,5.9%)(P<.001)。与 SARS-CoV-2 检测结果阴性的人相比,检测结果阳性的人发生孕产妇死亡的比例更高(3.7% vs. 0.1%)(校正相对风险[aRR]31.6,95%CI 15.4-64.7)。孕产妇死亡率不因 HIV 状况而异。SARS-CoV-2 感染者的后代经历了更多的不良出生结局(34.5% vs. 26.6%;aRR 1.2,95%CI 1.1-1.4)、严重不良出生结局(13.6% vs. 9.8%;aRR 1.2,95%CI 1.0-1.5)、早产(21.4% vs. 13.4%;aRR 1.4,95%CI 1.2-1.7)和死胎(5.6% vs. 2.7%;aRR 1.7,95%CI 1.2-2.5)。暴露于 SARS-CoV-2 和 HIV 感染的新生儿不良出生结局的发生率最高(43.1% vs. 22.6%;aRR 1.7,95%CI 1.4-2.0)。
在博茨瓦纳,分娩时感染 SARS-CoV-2 与 3.7%的孕产妇死亡率和 5.6%的死产有关。大多数不良出生结局在同时暴露于 SARS-CoV-2 和 HIV 的新生儿中更为严重。